BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on ...

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...

A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...

BridgeBio Pharma has received European approval for a drug that treats cardiomyopathy stemming from a rare metabolic condition, strengthening the biotech’s position to take market share from the ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new treatments launched by biotech startups. Late last week the FDA approved ...